Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...